Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18643595 | TOPICAL PHARMACEUTICAL COMPOSITIONS | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18607763 | FISH-DERIVED PEPTIDOGLYCAN RECOGNITION PROTEIN MUTANTAND APPLICATION THEREOF | March 2024 | August 2024 | Allow | 5 | 1 | 0 | No | No |
| 18583657 | METHODS FOR RAISING NITRIC OXIDE AND REDUCTION OF URIC ACID | February 2024 | March 2025 | Abandon | 13 | 2 | 0 | No | No |
| 18386411 | ETHYL 2-[9-(6-FLOURO-2-HYDROXYQUINOLIN-3-YL)-1,8-DIOXO-3,4,9,10-TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUND | November 2023 | February 2024 | Allow | 3 | 0 | 0 | No | No |
| 18242099 | Micronutrient composition to improve men health | September 2023 | March 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18448754 | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM | August 2023 | August 2024 | Abandon | 12 | 2 | 0 | Yes | No |
| 18448640 | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM | August 2023 | February 2025 | Abandon | 18 | 3 | 0 | Yes | No |
| 18172403 | ANTI-INFECTION AND ANTI-TUMOR MUCOSAL IMMUNE PREPARATION | February 2023 | January 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18162259 | MICROPARTICLES CONTAINING BUPROPION | January 2023 | February 2024 | Abandon | 13 | 2 | 0 | Yes | No |
| 18098361 | SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS | January 2023 | November 2024 | Allow | 22 | 1 | 0 | No | No |
| 17995021 | Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune/inflammatory diseases in humans or animals | September 2022 | May 2025 | Abandon | 32 | 0 | 1 | No | No |
| 17847951 | TYROSINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM | June 2022 | October 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17835805 | METHOD OF TREATING MIGRAINES AND HEADACHES | June 2022 | August 2023 | Allow | 14 | 3 | 0 | Yes | No |
| 17731403 | COMPOSITIONS AND METHODS FOR REDUCING AT LEAST ONE SYMPTOM OF HUMAN ALLERGY TO CATS | April 2022 | April 2024 | Allow | 24 | 2 | 0 | Yes | No |
| 17725189 | SOTALOL HYDROCHLORIDE DOSING | April 2022 | April 2025 | Allow | 36 | 1 | 0 | No | No |
| 17671540 | PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOF | February 2022 | September 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17579914 | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM | January 2022 | September 2023 | Allow | 20 | 3 | 0 | No | No |
| 17646935 | USE OF FRUCTOSE IN PREPARING DRUG FOR TREATING ISCHEMIC INJURY | January 2022 | December 2023 | Allow | 23 | 2 | 0 | No | No |
| 17560423 | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM | December 2021 | June 2022 | Allow | 6 | 2 | 0 | Yes | No |
| 17560392 | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM | December 2021 | June 2022 | Allow | 6 | 2 | 0 | Yes | No |
| 17552193 | MOLECULAR HYDROGEN-CONTAINING COMPOSITION FOR MAINTAINING LUNG FUNCTION IN HUMAN LUNG CANCER AND/OR IMPROVING REDUCTION IN LUNG FUNCTION ATTRIBUTED TO HUMAN LUNG CANCER | December 2021 | March 2024 | Abandon | 27 | 2 | 0 | No | No |
| 17541533 | METHODS AND COMPOSITIONS FOR TREATING HEART CONDITIONS | December 2021 | July 2024 | Allow | 32 | 2 | 0 | Yes | No |
| 17539595 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING RESPIRATORY DISORDERS | December 2021 | March 2023 | Abandon | 16 | 4 | 1 | Yes | Yes |
| 17537635 | PROCESS FOR THE PREPARATION OF A READY-TO-USE, COSMETIC, FLOWABLE DETERGENT | November 2021 | July 2024 | Allow | 32 | 1 | 1 | No | No |
| 17527401 | COMPOSITION AND METHOD FOR TREATMENT OF DIABETES | November 2021 | June 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17525841 | METHODS OF INCREASING BLOOD OXYGEN SATURATION | November 2021 | July 2024 | Allow | 32 | 4 | 1 | Yes | No |
| 17520323 | SYSTEM FOR PROVIDING BIRTH CONTROL | November 2021 | January 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17507957 | Electronic Device Sanitizer | October 2021 | December 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17507170 | ANTIMICROBIAL GUANIDINIUM MACROMOLECULES WITH BACTERIA TARGETING MOIETIES | October 2021 | April 2024 | Allow | 30 | 2 | 0 | Yes | No |
| 17500075 | Permeable and Semi Permeable Substrate and Substance | October 2021 | May 2024 | Allow | 31 | 2 | 0 | No | No |
| 17496351 | METHODS FOR PROVIDING THE BENEFITS OF METHIONINE RESTRICTION WITHOUT DIETARY RESTRICTION | October 2021 | March 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17492451 | COMPOSITION FOR PREVENTING AND TREATING MICROBIAL DISEASE | October 2021 | May 2024 | Abandon | 32 | 2 | 1 | Yes | No |
| 17485686 | DRUG DELIVERY SYSTEM WITH ENHANCED IMMUNE ACTIVE FUNCTION | September 2021 | March 2025 | Allow | 42 | 3 | 1 | No | No |
| 17468481 | PROTECTION OF MICROBIAL CELLS FROM ACIDIC DEGRADATION | September 2021 | October 2023 | Allow | 25 | 0 | 1 | Yes | No |
| 17466974 | MINERAL CATION COMPLEX COMPOSITIONS, FORMULATIONS THEROF, AND METHODS OF USE THEROF | September 2021 | December 2022 | Allow | 15 | 3 | 1 | No | No |
| 17411295 | ANTIBACTERIAL SURFACE TREATED COPPER MATERIAL AND A METHOD FOR PREPARING THE SAME | August 2021 | March 2023 | Allow | 19 | 0 | 0 | No | No |
| 17392507 | CHLORINE DIOXIDE SUSTAINED-RELEASING DISINFECTING NANO MATERIAL AND PREPARATION METHOD AND USE THEREOF | August 2021 | October 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17379255 | MULTI-NUTRIENT SUPPLEMENT COMPOSITION AND USES THEREOF | July 2021 | December 2023 | Allow | 29 | 1 | 0 | No | No |
| 17375349 | SANITIZING AND ODOR ELIMINATION COMPOSITION AND METHOD OF MAKING THE SAME | July 2021 | October 2024 | Abandon | 40 | 2 | 0 | No | No |
| 17340343 | THREE-PART MAKEUP REMOVER COMPOSITIONS | June 2021 | January 2024 | Allow | 31 | 1 | 1 | No | No |
| 17331904 | HAIR TREATMENT COMPOSITIONS | May 2021 | May 2024 | Allow | 36 | 2 | 1 | Yes | No |
| 17297238 | A NASAL SOLUTION WITH CLOSED BASIN NATURAL SPRING WATER CHARACTERISTIC AND METHOD FOR OBTAINING SAID NASAL SOLUTION | May 2021 | July 2024 | Allow | 37 | 1 | 1 | No | No |
| 17328992 | Preventing, treating, and curing illness by denaturing proteins and nucleic acids | May 2021 | August 2024 | Abandon | 38 | 1 | 1 | Yes | No |
| 17235592 | METHOD OF TREATING AND PREVENTING CORONAVIRUS DISEASE 19 (COVID-19) USING A SELENIUM ADMINISTRATION | April 2021 | January 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17286665 | SLEEP-IMPROVING COMPOSITIONS | April 2021 | September 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17233031 | NUTRITIONAL COMPOSITION FOR THE TREATMENT OF METABOLIC DISEASES | April 2021 | September 2023 | Allow | 29 | 1 | 0 | No | No |
| 17198928 | USE OF MORCHELLA ACTIVE SUBSTANCE | March 2021 | April 2025 | Abandon | 49 | 5 | 0 | No | No |
| 17192185 | DRUG THERAPY TO INHIBIT CHEMOTHERAPY-INDUCED ADVERSE EFFECTS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITS | March 2021 | July 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17188857 | SYSTEM FOR PROVIDING BIRTH CONTROL | March 2021 | April 2023 | Allow | 25 | 1 | 0 | No | No |
| 17267425 | METHOD OF PREPARING AN ANTIBODY PHARMACEUTICAL FORMULATION | February 2021 | December 2023 | Abandon | 34 | 3 | 0 | No | No |
| 17265195 | COMPOSITION CONTAINING A MUCOLYTIC AGENT FOR THE TREATMENT OF MUCUS HYPERSECRETION AND A DEVICE FOR THE DOSING THEREOF | February 2021 | November 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 17153622 | NOVEL CHRONOTHERAPY BASED ON CIRCADIAN RHYTHMS | January 2021 | May 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17147692 | METHOD AND MOLECULAR HYDROGEN-CONTAINING COMPOSITION FOR PROMOTION OF POSTOPERATIVE RECOVERY | January 2021 | February 2024 | Abandon | 37 | 3 | 0 | Yes | No |
| 17142060 | COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS | January 2021 | June 2023 | Abandon | 30 | 1 | 1 | Yes | No |
| 17126329 | SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS | December 2020 | October 2022 | Allow | 22 | 1 | 1 | No | No |
| 17120883 | MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF DIARRHEA AND INFLAMMATION IN THE GASTROINTESTINAL TRACT | December 2020 | January 2024 | Allow | 37 | 1 | 1 | No | No |
| 17108081 | HAIR CONDITIONER COMPOSITIONS CONTAINING BEHENAMIDOPROPYL DIMETHYLAMINE | December 2020 | December 2023 | Allow | 36 | 3 | 0 | No | No |
| 17108090 | HAIR CONDITIONER COMPOSITIONS WITH A PRESERVATIVE SYSTEM CONTAINING SODIUM BENZOATE AND GLYCOLS AND/OR GLYCERYL ESTERS | December 2020 | December 2023 | Allow | 36 | 3 | 0 | No | No |
| 17103013 | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM | November 2020 | October 2022 | Allow | 23 | 1 | 0 | No | No |
| 17103357 | PARENTERAL NUTRITION FORMULATION | November 2020 | March 2025 | Abandon | 51 | 5 | 1 | No | No |
| 16950189 | Medication for Alleviating Parkinson's Symptoms and Method of Administering | November 2020 | June 2022 | Abandon | 19 | 1 | 1 | No | No |
| 17055150 | PERSONAL CLEANSING SOAP BAR COMPOSITION | November 2020 | February 2024 | Allow | 39 | 1 | 1 | No | No |
| 17087829 | MOSQUITO CONTROL AEROSOL AND MOSQUITO CONTROL METHOD | November 2020 | November 2022 | Abandon | 24 | 1 | 0 | No | No |
| 17082698 | PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN | October 2020 | October 2022 | Allow | 23 | 3 | 0 | Yes | Yes |
| 17050875 | NEW SALT OF CYSTEAMINE FOR THE PREPARATION OF HIGHLY RESPIRABLE PARTICLES | October 2020 | January 2023 | Allow | 26 | 0 | 1 | No | No |
| 17048483 | A PHARMACEUTICAL DRY POWDER COMPOSITION FOR INHALATION COMPRISING A THYROID HORMONE | October 2020 | July 2023 | Allow | 32 | 3 | 0 | Yes | No |
| 17065818 | TOPICAL CANNABIDIOL COMPOSITION | October 2020 | January 2024 | Allow | 39 | 4 | 1 | Yes | No |
| 17041300 | LIQUID LIPID COMPOSITE COMPOSITION FOR IMPROVING HAIR CONDITION | September 2020 | November 2023 | Allow | 38 | 1 | 1 | Yes | No |
| 17009275 | METHODS AND COMPOSITIONS FOR TREATING HEART CONDITIONS | September 2020 | September 2021 | Allow | 13 | 2 | 1 | Yes | No |
| 16995388 | SYSTEM FOR PROVIDING BIRTH CONTROL | August 2020 | August 2022 | Allow | 24 | 1 | 0 | No | No |
| 16993503 | ENCAPSULATED ADIPOSE-DERIVED STEM CELLS, METHODS FOR PREPARATION AND THERAPUTIC USE | August 2020 | June 2022 | Allow | 22 | 1 | 0 | No | No |
| 16944614 | ULTRAVIOLET BLOCKING AGENT AND COSMETIC PRODUCT | July 2020 | March 2022 | Allow | 19 | 1 | 0 | No | No |
| 16941413 | NON-AQUEOUS PATCH FOR THE RELIEF OF PAIN | July 2020 | June 2023 | Allow | 35 | 2 | 0 | Yes | No |
| 16931630 | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM | July 2020 | June 2022 | Allow | 23 | 1 | 0 | Yes | No |
| 16946941 | METHOD OF CONVERTING ATRIAL FIBRILLATION TO NORMAL SINUS RHYTHM AND LOADING ORAL SOTALOL IN A SHORTENED TIME FRAME | July 2020 | March 2022 | Allow | 21 | 1 | 0 | No | No |
| 16961392 | NEW AGROCHEMICAL FORMULATIONS | July 2020 | December 2024 | Allow | 53 | 3 | 1 | No | No |
| 16919415 | PERSONAL CARE CLEANING COMPOSITIONS | July 2020 | August 2023 | Allow | 38 | 1 | 0 | Yes | No |
| 16959368 | Stable Liquid Compositions of Melphalan | June 2020 | February 2023 | Abandon | 32 | 0 | 1 | No | No |
| 16911589 | ANTIMICROBIAL LATEX OR RUBBER PRODUCTS MADE USING A (NANO)COMPOSITE ZINC OXIDE, AND COMPOSITIONS AND METHODS FOR MAKING SUCH PRODUCTS | June 2020 | December 2021 | Abandon | 18 | 2 | 0 | Yes | No |
| 16901909 | NOVEL ANTIARRHYTHMIC FORMULATION | June 2020 | March 2021 | Allow | 9 | 1 | 0 | Yes | No |
| 16901941 | ANTIARRHYTHMIC FORMULATION | June 2020 | March 2021 | Allow | 9 | 1 | 0 | Yes | No |
| 16853905 | MOSQUITO ATTRACTANT FORMULATIONS AND USES THEREOF | April 2020 | December 2022 | Allow | 32 | 1 | 1 | Yes | No |
| 16851096 | ATTRACTANT OF LADYBUGS, APHID'S NATURAL ENEMY | April 2020 | January 2021 | Allow | 9 | 1 | 0 | Yes | No |
| 16849099 | INTRAVENOUS SOTALOL HYDROCHLORIDE LOADING AND MAINTENANCE FOR CARDIAC SURGERY PATIENTS | April 2020 | August 2021 | Abandon | 16 | 2 | 0 | No | No |
| 16842939 | SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS | April 2020 | September 2020 | Allow | 5 | 1 | 0 | No | No |
| 16827388 | SYSTEM FOR PROVIDING BIRTH CONTROL | March 2020 | December 2020 | Allow | 9 | 1 | 0 | No | No |
| 16824111 | COMPOSITION FOR TREATING OR PREVENTING METABOLIC DISEASE, CONTAINING, AS ACTIVE INGREDIENT, EXTRACELLULAR VESICLES DERIVED FROM AKKERMANSIA MUCINIPHILA BACTERIA | March 2020 | December 2021 | Allow | 21 | 3 | 0 | No | No |
| 16819290 | Method for Unlocking Bioactive Proteins | March 2020 | March 2021 | Allow | 12 | 1 | 0 | No | No |
| 16814724 | SYSTEM FOR PROVIDING BIRTH CONTROL | March 2020 | December 2020 | Allow | 9 | 1 | 0 | Yes | No |
| 16801961 | MDI RELATED PRODUCTS AND METHODS OF USE | February 2020 | August 2022 | Abandon | 30 | 4 | 0 | No | No |
| 16640359 | DURABLE PEST-REPELLING FORMULATIONS | February 2020 | February 2023 | Allow | 36 | 1 | 1 | No | No |
| 16780226 | AFFINITY BASED DRUG RELEASE FORMULATIONS | February 2020 | February 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 16731889 | HAIR AND SCALP NUTRITION FOR PSORIASIS AND ECZEMA | December 2019 | July 2022 | Abandon | 30 | 0 | 1 | No | No |
| 16727906 | COMPOSITIONS, DISPENSING SYSTEMS AND METHODS FOR PROVIDING SENSORIAL AND AESTHETIC BENEFITS TO ACNE PRONE SKIN | December 2019 | May 2024 | Abandon | 53 | 4 | 1 | No | No |
| 16616904 | RINSE-OFF CONDITIONER COMPOSITIONS COMPRISING MICROCAPSULES | November 2019 | October 2023 | Allow | 47 | 4 | 1 | Yes | No |
| 16690379 | Intramammary Veterinary Composition | November 2019 | September 2023 | Abandon | 46 | 2 | 1 | No | No |
| 16690784 | WOUND DRESSING MATERIALS INCORPORATING ANTHOCYANINS DERIVED FROM FRUIT OR VEGETABLE SOURCES | November 2019 | December 2023 | Abandon | 48 | 3 | 0 | No | No |
| 16676618 | ROACH GEL FORMULATIONS | November 2019 | February 2024 | Allow | 51 | 5 | 0 | Yes | No |
| 16663173 | MULTI-STAGE BIODEGRADABLE DRUG DELIVERY PLATFORM | October 2019 | December 2023 | Allow | 50 | 5 | 0 | No | No |
| 16587833 | TOPICAL PHARMACEUTICAL COMPOSITIONS | September 2019 | January 2023 | Allow | 40 | 4 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NGUYEN, JOHN P.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 11.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner NGUYEN, JOHN P works in Art Unit 1619 and has examined 418 patent applications in our dataset. With an allowance rate of 44.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner NGUYEN, JOHN P's allowance rate of 44.3% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by NGUYEN, JOHN P receive 2.60 office actions before reaching final disposition. This places the examiner in the 88% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by NGUYEN, JOHN P is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +39.8% benefit to allowance rate for applications examined by NGUYEN, JOHN P. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 14.5% of applications are subsequently allowed. This success rate is in the 5% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 20.3% of cases where such amendments are filed. This entry rate is in the 17% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 75.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 58% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 58.3% of appeals filed. This is in the 27% percentile among all examiners. Of these withdrawals, 57.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 63.0% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.0% of allowed cases (in the 68% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.